Table 3.

OS for the 7/8 HLA-MMUD HCT weighted samples in the for the abatacept + CNI/MTX vs CNI/MTX comparison cohort

Abatacept + CNI/MTX (n = 54)CNI/MTX (n = 161)P value 
Day 180 (primary end point)    
OS (95% CI) 98 (78-100) 75 (67-82) .0028 
HR (95% CI)  0.06 (0.01-0.27)   
1 y    
OS (95% CI) 86 (68-95) 61 (53-69) .0046 
HR (95% CI)  0.28 (0.12-0.68)   
2 y    
OS (95% CI) 83 (64-92) 55 (46-63) .0036 
HR (95% CI)  0.30 (0.14-0.65)   
Abatacept + CNI/MTX (n = 54)CNI/MTX (n = 161)P value 
Day 180 (primary end point)    
OS (95% CI) 98 (78-100) 75 (67-82) .0028 
HR (95% CI)  0.06 (0.01-0.27)   
1 y    
OS (95% CI) 86 (68-95) 61 (53-69) .0046 
HR (95% CI)  0.28 (0.12-0.68)   
2 y    
OS (95% CI) 83 (64-92) 55 (46-63) .0036 
HR (95% CI)  0.30 (0.14-0.65)   

OS is defined as the time between the date of transplant to the physician documented date of death. Patients were censored at 181 days and 1 year after transplant or at time of last follow-up, whichever is earlier. Propensity scores obtained from a logistic regression model including sex, disease, age, HCT graft source, conditioning intensity, Karnofsky/Lansky performance score, and CNI type, as covariates.

Based on weighted Kaplan-Meier method.

Marginal HR based on weighted Cox proportional hazards model with treatment as the only covariate using a robust variance estimator that accounts for the sample weights. Ties are handled using the Breslow method.

or Create an Account

Close Modal
Close Modal